Advanced Therapy Medicinal Products for Eye Diseases: Goals and Challenges
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: closed (1 July 2021) | Viewed by 44815
Special Issue Editors
2. Instituto Universitario de Oftalmobiología Aplicada (IOBA), Universidad de Valladolid, Paseo de Belén 17, 47011 Valladolid, Spain
3. Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III, Valladolid, Spain
Interests: advanced therapy; biomaterials; cell culture; conjunctiva; cornea; drug delivery; inflammation; nanomedicine; ocular surface
Interests: advanced therapy; cell culture; conjunctiva; cornea; dry eye disease; inflammation; in vitro models; ocular surface
Special Issue Information
Dear Colleagues,
The concept of advanced therapy medicinal products (ATMPs) encompasses novel kinds of medicines for human use that are based on genes, cells or tissues. These intend to offer not only regeneration but complete functional recovery of diseased tissues and organs using different strategies. Gene therapy, cell therapy and tissue engineering are the main areas in which promising advanced therapies are emerging. The eye is a very complex organ whose main structures, the cornea and the retina, play a pivotal role in maintaining normal vision, as severe alterations in these tissues can lead to blindness. Ocular tissues are starting to benefit from ATMPs by fighting against the enormous complexity and devastating potential of many ocular diseases. However, developments arising from this field of work face important challenges related to vectors to deliver drugs and genetic material to target tissues, suitable biomaterials to prepare cell scaffolds and cell stemness, among others—not to mention the complicated legislation around ATMPs, the complexity in production and quality control and the absence of standardized protocols.
The purpose of this Special Issue is to serve as an overview of the current progress in the application of cell and gene therapies as well as tissue engineering to restore functionality in diseased ocular structures and the challenges linked to reaching patients.
This Special Issue will cover the following topics but is not limited to them:
- ATMPs legislation and major challenges in ophthalmology;
- Pharmacology-related issues with ATMPs for the eye;
- In vitro, ex vivo and in vivo models to test ATMPs;
- Gene therapy for corneal and retinal diseases;
- Stem cell therapy in the eye: ocular surface diseases, glaucoma, retinal degeneration;
- Eye tissue banking and other sources of human ocular tissues for regenerative medicine;
- Biomaterials for ophthalmic applications;
- Tissue engineering for ocular tissues.
Research scientists and clinicians working in any of these fields or related ones are invited to contribute to this Special Issue by submitting original research articles, review articles or expert opinions.
Prof. Dr. Yolanda Diebold
Dr. Laura García-Posadas
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
翻译 朗读 复制 正在查询,请稍候…… 重试 朗读 复制 复制 朗读 复制 via 谷歌翻译(国内) 译Keywords
- advanced therapy
- biomaterial
- cell therapy
- cornea
- drug delivery
- eye
- gene delivery
- gene therapy
- retina
- scaffold
- tissue engineering